Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018222186) OPTIMIZATION OF AN ACTIVE PCSK9 ASSAY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/222186 International Application No.: PCT/US2017/035216
Publication Date: 06.12.2018 International Filing Date: 31.05.2017
IPC:
A61K 38/17 (2006.01) ,G01N 33/53 (2006.01) ,G01N 33/541 (2006.01) ,G01N 33/566 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
536
with immune complex formed in liquid phase
537
with separation of immune complex from unbound antigen or antibody
539
involving precipitating reagent
541
Double or second antibody
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
566
using specific carrier or receptor proteins as ligand binding reagent
Applicants:
NORTH CAROLINA CENTRAL UNIVERSITY [US/US]; 1801 Fayetteville Street Durham, North Carolina 27707, US
Inventors:
LOPEZ, Dayami; US
Agent:
CORD, Janet I.; US
RICHARDS, John; US
MASS, Clifford J.; US
DIPERNA, Raymond A.; US
Priority Data:
Title (EN) OPTIMIZATION OF AN ACTIVE PCSK9 ASSAY
(FR) OPTIMISATION D’UN DOSAGE DE PCSK9 ACTIF
Abstract:
(EN) An assay and a method for detecting how much active PCSK9 is available in a sample to bind to the LDL receptor. Active PCSK9 is PCSK9 that is not bound to a LDL receptor and is available to bind to a LDL receptor. An aspect of the assay and method involves the use of LDL receptor and a PCSK9 specific antibody to identify, detect or quantify the PCSK9/LDL receptor complexes.
(FR) La présente invention concerne un dosage et un procédé de détection de la quantité de PCSK9 actif qui est disponible dans un échantillon pour se lier au récepteur de LDL. PCSK9 actif est PCSK9 qui n’est pas lié à un récepteur de LDL et est disponible pour se lier à un récepteur de LDL. Un aspect du dosage et du procédé met en œuvre l’utilisation d’un récepteur de LDL et d’un anticorps spécifique contre PCSK9 pour identifier, détecter ou quantifier les complexes PCSK9/récepteur de LDL.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)